PharmaShots | Incisive News in 3 Shots

Subscribe Now

viatris

Viatris Join Forces with Lexicon Pharmaceuticals to Commercialize Sotagliflozin Across all Markets Outside of the US and EU

Viatris Join Forces with Lexicon Pharmaceuticals to Commercialize Sotagliflozin Across all Markets Outside of the US and EU

October 17, 2024

Viatris Collaborates with Idorsia to Develop and Commercialize Selatogrel and Cenerimod

Viatris Collaborates with Idorsia to Develop and Commercialize Selatogrel and Cenerimod

February 28, 2024

Viatris and Ocuphire Pharma Receive the US FDA’s Approval of Ryzumvl (Phentolamine Ophthalmic Solution) for Pharmacologically-Induced Mydriasis

Viatris and Ocuphire Pharma Receive the US FDA’s Approval of Ryzumvl (Phentolamine Ophthalmic Solution) for Pharmacologically-Indu...

September 28, 2023

Viatris and Mapi Pharma Report the US FDA Acceptance of NDA for GA Depot to Treat Relapsing Forms of Multiple Sclerosis

Viatris and Mapi Pharma Report the US FDA Acceptance of NDA for GA Depot to Treat Relapsing Forms of Multiple Sclerosis

August 8, 2023

Viatris and Sandoz Report Results of Hulio and Hyrimoz (biosimilar, adalimumab) for the Treatment of Inflammatory Bowel Disease

Viatris and Sandoz Report Results of Hulio and Hyrimoz (biosimilar, adalimumab) for the Treatment of Inflammatory Bowel Disease

August 11, 2022

Viatris and Biocon Launched Abevmy (biosimilar, bevacizumab) for the Treatment of Cancer in Canada

Viatris and Biocon Launched Abevmy (biosimilar, bevacizumab) for the Treatment of Cancer in Canada

May 19, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us